BPTH Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical & preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.

$6.84
As of 04/09/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/11/2006
Outstanding shares:  6,947,912
Average volume:  1,398,677
Market cap:   $47,523,718
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    09057N300
ISIN:        US09057N3008
Sedol:      BJ2L058
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.23
PS ratio:   0.00
Return on equity:   -72.21%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy